TY - JOUR
T1 - Nanotechnology and nanomedicine
T2 - Going small means aiming big
AU - Teli, Mahesh Kumar
AU - Mutalik, Srinivas
AU - Rajanikant, G. K.
PY - 2010
Y1 - 2010
N2 - Nanotechnology is an emerging branch of science for designing tools and devices of size 1 to 100 nm with specific function at the cellular, atomic and molecular levels. The concept of employing nanotechnology in biomedical research and clinical practice is best known as nanomedicine. Nanomedicine is an upcoming field that could potentially make a major impact to human health. Nanomaterials are increasingly used in diagnostics, imaging and targeted drug delivery. Nanotechnology will assist the integration of diagnostics/imaging with therapeutics and facilitates the development of personalized medicine, i.e. prescription of specific medications best suited for an individual. This review provides an integrated overview of application of nanotechnology based molecular diagnostics and drug delivery in the development of nanomedicine and ultimately personalized medicine. Finally, we identify critical gaps in our knowledge of nanoparticle toxicity and how these gaps need to be evaluated to enable nanotechnology to transit safely from bench to bedside.
AB - Nanotechnology is an emerging branch of science for designing tools and devices of size 1 to 100 nm with specific function at the cellular, atomic and molecular levels. The concept of employing nanotechnology in biomedical research and clinical practice is best known as nanomedicine. Nanomedicine is an upcoming field that could potentially make a major impact to human health. Nanomaterials are increasingly used in diagnostics, imaging and targeted drug delivery. Nanotechnology will assist the integration of diagnostics/imaging with therapeutics and facilitates the development of personalized medicine, i.e. prescription of specific medications best suited for an individual. This review provides an integrated overview of application of nanotechnology based molecular diagnostics and drug delivery in the development of nanomedicine and ultimately personalized medicine. Finally, we identify critical gaps in our knowledge of nanoparticle toxicity and how these gaps need to be evaluated to enable nanotechnology to transit safely from bench to bedside.
UR - http://www.scopus.com/inward/record.url?scp=77953525110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953525110&partnerID=8YFLogxK
U2 - 10.2174/138161210791208992
DO - 10.2174/138161210791208992
M3 - Article
C2 - 20222866
AN - SCOPUS:77953525110
SN - 1381-6128
VL - 16
SP - 1882
EP - 1892
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 16
ER -